DUBLIN--(BUSINESS WIRE)--Research and Markets(http://www.researchandmarkets.com/research/8497b4/global_hemophilia) has announced the addition of the "Global Hemophilia Treatment Market 2010-2014" report to their offering.
One of the key factors contributing to this market growth is hemophilia is an inherited disorder. The Global Hemophilia Treatment market has also been witnessing the trend of home hemophilia treatment therapy. However, high cost of treatment could pose a challenge to the growth of this market.
TechNavio's report, Global Hemophilia Treatment Market 2010-2014, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hemophilia Treatment market landscape and its growth prospects in the coming years.
This report includes treatments for hemophilia A, B, and C, namely, recombinant factor VIII and coagulation factor IX, and Desmopressin (DDAVP) which stimulates the release of factor VIII and also increases the level of proteins in the blood.
Key vendors dominating this market space include Baxter Healthcare Corp., Novo Nordisk A/S, Bayer Healthcare Pharmaceuticals Inc., and Pfizer Inc.
Commenting on the report, an analyst from TechNavio's Healthcare team said, A key driver for the growth of this market is various government comprehensive care programs running for the treatment of hemophilia. These programs aim to provide improved health, decreased hospitalization accompanied by decreased costs of care. Moreover, vendors are also supporting such comprehensive care programs in the form of campaigns. For instance, Novo Nordisk supports the "It's Time for a Cure campaign among various other programs for the bleeding disorders community.
According to the report, mergers and acquisitions has become the core growth strategy for many healthcare vendors. It has become the growth avenue for product expansion, competitive advantage, and greater market share. The Global Hemophilia Treatment market is also witnessing a similar trend of strategic alliance for increasing the market share and global presence. For instance, in 2010, Baxter entered into a definitive agreement to acquire all the hemophilia-related assets of Archemix, a privately held biopharmaceutical company.
For more information visit http://www.researchandmarkets.com/research/8497b4/global_hemophilia